WARRINGTON, Pa., Nov. 15, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO), a biotechnology company developing its novel, synthetic, peptide-containing surfactant and related aerosolization technologies as first-in-class therapies for severe respiratory diseases, announced today that Dr. Thomas F. Miller, Chief Operating Officer of Discovery Labs, will present at the Lazard Capital Markets 7th Annual Healthcare Conference on November 17, 2010 in New York. The conference will be simultaneously webcast over the Internet.
Dr. Miller is scheduled to present at 9:00 AM EST on Wednesday, November 17, 2010. The presentation will be available through a live audio webcast at http://www.wsw.com/webcast/lz8/dsco/ or Discovery Labs' web site, www.discoverylabs.com. A replay of the audio webcast will be available on both websites for ninety days.
About Discovery Labs
Discovery Laboratories, Inc. is a biotechnology company developing KL4 surfactant therapies for respiratory diseases. Surfactants are produced naturally in the lungs and are essential for breathing. Discovery Labs' novel proprietary KL4 surfactant technology produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant and is being developed in liquid, aerosol and lyophilized formulations. In addition, Discovery Labs' proprietary capillary aerosolization technology produces a dense aerosol, with a defined particle size that is capable of potentially delivering aerosolized KL4 surfactant to the deep lung without the complications currently associated with liquid surfactant administration. Discovery Labs believes that its proprietary technology platform makes it possible, for the first time, to develop a significant pipeline of surfactant products to address a variety of respiratory diseases for which there frequently are few or no approved therapies. For more information, please visit our website at www.Discoverylabs.com.